Viemed Healthcare, Inc. (VMD) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Viemed Healthcare, Inc. is a provider of home medical equipment (HME) and post-acute respiratory healthcare services in the United States, serving patients in all 50 states. The company focuses on respiratory, chronic care, and women's health products. As of March 31, 2026, the company employed 1,387 full-time employees, including 403 licensed respiratory therapists.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $75,414 | $59,129 |
| Gross Profit | $42,827 | $33,279 |
| Gross Margin | 56.8% | 56.3% |
| Net Income (GAAP) | $2,713 | $2,710 |
| Net Income Attributable to Viemed | $2,582 | $2,625 |
| Diluted EPS | $0.06 | $0.06 |
| Adjusted EBITDA | $14,311 | $12,765 |
| Cash from Operations | $8,071 | $2,854 |
| Cash and Equivalents (End of Period) | $9,762 | $10,160 |
| Total Debt (Principal) | $9,625 | $12,867 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 27.5% year-over-year to $75.4 million. This was driven by a 132.6% surge in equipment and supply sales (largely due to the Lehan acquisition and sleep resupply growth) and a 10.0% increase in ventilator rentals.
- Profitability: While GAAP net income remained flat, Adjusted EBITDA grew 12.1% to $14.3 million. The flat net income in Q1 2026 compared to Q1 2025 is largely due to the absence of a $2.4 million gain on the disposal of property and equipment (ventilator buyback) recorded in the prior year.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 22.4% to $34.8 million, primarily due to increased employee-related costs supporting growth and integration of the Lehan acquisition. However, SG&A as a percentage of revenue improved to 46.1% from 48.1%.
- Debt Reduction: Total debt principal decreased by approximately $3.2 million to $9.6 million, reflecting principal payments on the 2022 Term Loan Facility.
- Acquisition Impact: The July 2025 acquisition of Lehan Drugs, Inc. contributed to revenue growth in the women's health and maternal health segments.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue growing through geographic expansion and workforce scaling. The company anticipates gross margins to gradually improve as fulfillment efficiencies are realized in sales-oriented service lines.
- Regulatory Environment: The company is monitoring the impact of the final National Coverage Determination (NCD) issued by CMS in June 2025 regarding ventilator use, which establishes specific medical necessity criteria. Additionally, the "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 introduces changes to Medicaid and Medicare that may impact reimbursement and eligibility, with provisions taking effect as early as 2026.
- Liquidity: The company maintains a $30 million revolving credit facility and a $30 million delayed draw term loan facility (maturing November 2027). As of March 31, 2026, there were no borrowings under the revolving facility. Management believes current cash and operating cash flows are sufficient for the next 12 months.
- Share Repurchases: A new 2026 Share Repurchase Program was authorized in March 2026, allowing for the repurchase of up to 1,930,131 shares. The company repurchased 150,000 shares during Q1 2026.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 132.6% growth in equipment sales, which is heavily influenced by the recent Lehan acquisition and sleep resupply scaling.
- Regulatory Impact: Assess the potential financial impact of the new CMS ventilator NCD and the OBBBA legislation on future reimbursement rates and patient eligibility.
- Working Capital: Monitor the $5.6 million increase in accounts receivable, which contributed to a reduction in operating cash flow relative to net income.
- Debt Covenants: Confirm continued compliance with the Consolidated Total Leverage Ratio (max 2.50:1.0) and Fixed Charge Coverage Ratio (min 1.25:1.0) under the 2022 Senior Credit Facilities.
- Non-GAAP Reconciliation: Review the reconciliation of Net Income to Adjusted EBITDA to understand the impact of non-cash items like stock-based compensation ($2.5 million) and depreciation ($7.6 million).